QPS NEUROPHARMACOLOGY

Preclinical CRO for

Get in touchService navigator

QPS Neuropharmacology is the division of QPS that focuses on preclinical studies in CNS diseases, Orphan Diseases and Mental Disorders. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS Neuropharmacology the first choice for most CNS drug development needs.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader in the CRO industry, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.

The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

Why choose us?

Customer satisfaction is our absolute priority

Your timeline is our timeline

f

Every study is custom-built

p

Scientific input to study design and data interpretation

Extensive experience with virtually all drug targets and treatment types

0

Wide range of validated models and techniques for comprehensive compound tests from a single source

AAALAC certification ensures highest quality standards

QPS Austria AAALAC accrediation Logo

QPS NEURO NEWS

February 2020 - Neuroinflammation in the Niemann-Pick disease mouse model NPC1-/-

Neuroinflammation is a growing field of research in the fight against neurodegenerative diseases and other disorders affecting the central nervous system. We have previously shown that NPC1-/- mice exhibit strong inflammation (Santiago-Mujica et al., 2019). To further elucidate inflammation in the brain of NPC1-/- mice, we now evaluated CD45 analysis in the thalamus (A) and substantia nigra (B). Our results show that the CD45 immunoreactive area is strongly increased in the thalamus and substantia nigra of 8 week old NPC1-/- mice compared to wild type control animals. Detailed analysis reveals that the density of CD45 labeled cells and the size of these cells is highly increased (data not show).

Figure 1. Quantification of CD45-positive macrophages in the thalamus and substantia nigra of NPC1-/- mice. The thalamus (A) and substantia nigra (B) of 8 week old NPC1-/- mice were investigated for CD45-positive cells of the immune system. Immunoreactive area (IR) in percent compared to control littermates is shown. Unpaired t-test. n = 8 per group. Mean + SEM. ***p<0.001. C: Representative images of CD45 (green) and DAPI (blue) labeling of sagittal brain sections of an 8 week old NPC1-/- and a control mouse.

 


 

February 25-27

Meet us at the

8th Annual Neurodegenerative Drug Development Summit

in Boston, Massachusetts, USA

QPS will be attending the NDD Summit and we are pleased to meet you at our booth.

 

Join us February 25-27 at the Hyatt Regency Boston, Boston, MA, USA

In Vitro Services

QPS Austria’s Neuropharmacology Department provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.

In Vivo Services

We have more than 15 years experience in generating, characterizing and maintaining transgenic disease models and using them for drug testing projects. Several customized behavioral tests, including motor, cognitive, and emotional assays, are offered to phenotype mouse and rat models and to evaluate effects of compounds in different in vivo models.

Ex Vivo Services

Our ex vivo services cover a full range of histological services, a biobank composed of various specimen derived from our in-house in vivo and in vitro models, and numerous well established tests for biomarkers. We are happy to test new protocols and establish new markers to meet your specific needs.

Facebook
Twitter
LinkedIn